In a corsortium with Villagra (The George Washington University, D.C.) and Wardrop (University of Illinois at Chicago, IL) labs we have been awarded an R01 grant! The grant is aimed at the development of selective HDAC6 inhibitors with an improved ability to reduce the expression of negative immune checkpoint molecules in cancer immunotherapy.